Suppr超能文献

多巴胺1受体激动剂静脉注射非诺多泮在高血压患者中的药代动力学和药效学特性。

Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients.

作者信息

Weber R R, McCoy C E, Ziemniak J A, Frederickson E D, Goldberg L I, Murphy M B

机构信息

Department of Pharmacological and Physiological Science, University of Chicago, Illinois 60637.

出版信息

Br J Clin Pharmacol. 1988 Jan;25(1):17-21. doi: 10.1111/j.1365-2125.1988.tb03276.x.

Abstract

1 The pharmacokinetic properties of intravenous fenoldopam, a selective dopamine1-receptor agonist, were studied in 10 patients with essential hypertension. 2 Reduction in blood pressure was linearly related to the log fenoldopam plasma concentration (r = 0.69) and the log fenoldopam infusion rate (r = 0.71). 3 The mean elimination half-life (+/- s. e. mean) was 9.8 +/- 1.0 min. The total body clearance was 30.3 +/- 2.3 ml kg-1 min-1 and the volume of distribution was 582 +/- 62 ml kg-1. 4 The rapid onset of action, short elimination half-life, linear dose-response relationship, and ease of administration suggest that fenoldopam may have a role where parenteral treatment of hypertension is required.

摘要
  1. 在10例原发性高血压患者中研究了静脉注射选择性多巴胺1受体激动剂非诺多泮的药代动力学特性。2. 血压降低与非诺多泮血浆浓度的对数呈线性相关(r = 0.69),与非诺多泮输注速率的对数也呈线性相关(r = 0.71)。3. 平均消除半衰期(±标准误)为9.8±1.0分钟。全身清除率为30.3±2.3 ml·kg⁻¹·min⁻¹,分布容积为582±62 ml·kg⁻¹。4. 起效迅速、消除半衰期短、剂量反应关系呈线性以及易于给药表明,在需要胃肠外治疗高血压的情况下,非诺多泮可能有一定作用。

相似文献

2
Cardiovascular and renal profile of acute peripheral dopamine1-receptor agonism with fenoldopam.
Hypertension. 1987 Jul;10(1):43-54. doi: 10.1161/01.hyp.10.1.43.
4
Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam.
J Am Coll Cardiol. 1988 May;11(5):1118-23. doi: 10.1016/s0735-1097(98)90073-0.
9
Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension.
Br J Clin Pharmacol. 1986 Jan;21(1):53-61. doi: 10.1111/j.1365-2125.1986.tb02822.x.

引用本文的文献

1
Fenoldopam for preventing and treating acute kidney injury.
Cochrane Database Syst Rev. 2024 Nov 28;11(11):CD012905. doi: 10.1002/14651858.CD012905.pub2.
3
Fenoldopam and renal hemodynamics in shiga toxin-related hemolytic uremic syndrome.
Pediatr Nephrol. 2021 Sep;36(9):2891-2894. doi: 10.1007/s00467-021-05127-3. Epub 2021 May 17.
4
Effects of Fenoldopam in the Pediatric Population: Fluid Status, Serum Biomarkers, and Hemodynamics: A Systematic Review and Meta-Analysis.
J Pediatr Intensive Care. 2021 Jun;10(2):118-125. doi: 10.1055/s-0040-1714704. Epub 2020 Aug 10.
5
Dopamine D1 Receptor in Cancer.
Cancers (Basel). 2020 Nov 2;12(11):3232. doi: 10.3390/cancers12113232.
6
Exercise activates vagal induction of dopamine and attenuates systemic inflammation.
Brain Behav Immun. 2019 Jan;75:181-191. doi: 10.1016/j.bbi.2018.10.005. Epub 2018 Oct 27.
7
Dopaminergic Control of Inflammation and Glycemia in Sepsis and Diabetes.
Front Immunol. 2018 May 4;9:943. doi: 10.3389/fimmu.2018.00943. eCollection 2018.
8
Effects of fenoldopam on renal blood flow in hypertensive chronic kidney disease.
J Nephrol. 2019 Feb;32(1):75-81. doi: 10.1007/s40620-018-0496-0. Epub 2018 May 15.
9
Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer.
Oncogene. 2016 Jun 16;35(24):3103-13. doi: 10.1038/onc.2015.369. Epub 2015 Oct 19.
10
Dopamine mediates vagal modulation of the immune system by electroacupuncture.
Nat Med. 2014 Mar;20(3):291-5. doi: 10.1038/nm.3479. Epub 2014 Feb 23.

本文引用的文献

1
5
A new oral renal vasodilator, fenoldopam.
Clin Pharmacol Ther. 1983 Sep;34(3):309-15. doi: 10.1038/clpt.1983.173.
7
The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics.
Clin Pharmacol Ther. 1987 Mar;41(3):282-8. doi: 10.1038/clpt.1987.29.
8
The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro.
Br J Clin Pharmacol. 1986 Nov;22(5):535-40. doi: 10.1111/j.1365-2125.1986.tb02932.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验